Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX) Stock Resumes Another Round Of Rally: But Why?

September 10, 2021

Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX) jumped 10% after the US FDA granted the company Fast track designation for its drug candidate, ELX-02, to treat patients with cystic fibrosis with nonsense alterations. Currently, the drug candidate is in second phase clinical studies in cystic fibrosis patients with the nonsense mutation in the CF transmembrane conductance regulator (CFTR) gene who don’t have any available efficient disease-modifying treatments available. Most importantly, the second phase…

Read More >>